Precision Optics Corporation, Inc. income statement
In fiscal 2026, Precision Optics Corporation, Inc. reported revenue of $31.5m, up 65.2% on the year before, operating income of −$3.5m (a -11.1% margin) and net income of −$3.6m, or −$0.43 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.
Income statement
| Fiscal year | 2011Jun 2011 | 2012Jun 2012 | 2013Jun 2013 | 2014Jun 2014 | 2015Jun 2015 | 2016Jun 2016 | 2017Jun 2017 | 2018Jun 2018 | 2019Jun 2019 | 2020Jun 2020 | 2021Jun 2021 | 2022Jun 2022 | 2023Jun 2023 | 2024Jun 2024 | 2025Jun 2025 | 2026Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2 | 2 | 3 | 4 | 4 | 4 | 3 | 4 | 7 | 10 | 11 | 16 | 21 | 19 | 19 | 32 |
| Cost of revenue | — | — | — | — | — | — | 2 | 3 | 5 | 7 | 7 | 11 | 13 | 13 | 16 | 26 |
| Gross profit | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 3 | 3 | 5 | 8 | 6 | 3 | 5 |
| Research and development | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Selling, general and administrative | 1 | 1 | 1 | 2 | 2 | 2 | 1 | 1 | 2 | 4 | 4 | 6 | 7 | 8 | 8 | 8 |
| Operating income | −1 | −1 | −1 | −1 | −1 | −1 | −1 | −0 | −1 | −1 | −1 | −2 | −1 | −3 | −6 | −4 |
| Interest expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income before tax | — | 1 | −2 | −1 | −1 | −1 | −1 | −0 | −1 | −1 | −0 | −1 | −0 | −3 | −6 | −4 |
| Income tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income | −1 | 1 | −2 | −1 | −1 | −1 | −1 | −0 | −1 | −1 | −0 | −1 | −0 | −3 | −6 | −4 |
| Diluted EPS | −$1.06 | $2.34 | −$0.51 | −$0.26 | −$0.19 | −$0.15 | −$0.12 | −$0.04 | −$0.05 | −$0.11 | −$0.01 | −$0.18 | −$0.03 | −$0.49 | −$0.85 | −$0.43 |
| Diluted shares (average) | — | — | 1m | 1m | 2m | 2m | 3m | 3m | 4m | 4m | 4m | 5m | 6m | 6m | 7m | 9m |
| EBITDA | −1 | −1 | −1 | −1 | −1 | −1 | −1 | −0 | −1 | −1 | −1 | −1 | −0 | −3 | −5 | −3 |
| Quarter | 2025 Q1Sept 2024 | 2025 Q2Dec 2024 | 2025 Q3Mar 2025 | 2025 Q4Jun 2025 | 2026 Q1Sept 2025 | 2026 Q2Dec 2025 | 2026 Q3Mar 2026 | 2026 Q4Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 4,197 | 4,527 | 4,186 | 6,181 | 6,681 | 7,368 | 8,709 | 8,774 |
| Cost of revenue | 3,080 | 3,457 | 3,768 | 5,382 | 5,734 | 7,163 | 6,652 | 6,551 |
| Gross profit | 1,117 | 1,070 | 418 | 799 | 946 | 205 | 2,057 | 2,224 |
| Research and development | 401 | 318 | 211 | 228 | 312 | 250 | 267 | 204 |
| Selling, general and administrative | 1,964 | 1,662 | 2,245 | 1,927 | 2,230 | 1,697 | 1,854 | 2,126 |
| Operating income | −1,247 | −910 | −2,038 | −1,356 | −1,595 | −1,742 | −64 | −107 |
| Interest expense | 64 | 60 | 58 | 45 | 42 | 38 | 35 | 33 |
| Income before tax | — | — | −2,097 | −1,401 | — | — | −100 | −108 |
| Income tax | — | — | 0 | 2 | — | — | 9 | −4 |
| Net income | −1,311 | −970 | −2,097 | −1,403 | −1,637 | −1,781 | −108 | −104 |
| Diluted EPS | −$0.21 | −$0.15 | −$0.30 | −$0.18 | −$0.21 | −$0.23 | −$0.01 | $0.03 |
| EBITDA | −1,199 | −861 | −1,976 | −1,303 | −1,530 | −1,668 | 11 | −42 |
Compare with peers
- Orchestra Biomed Holdings, Inc. income statement
- Stereotaxis, Inc. income statement
- Retractable Technologies Inc income statement
- Utah Medical Products Inc income statement
- Electrocore, Inc. income statement
Head to head: OBIO vs POCIPOCI vs STXSPOCI vs RVP
More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies